|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Rat TNFSF8 ORF mammalian expression plasmid, C-GFPSpark tag||RG80148-ACG|
|Rat TNFSF8 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80148-ACR|
|Rat TNFSF8 ORF mammalian expression plasmid, C-Flag tag||RG80148-CF|
|Rat TNFSF8 ORF mammalian expression plasmid, C-His tag||RG80148-CH|
|Rat TNFSF8 ORF mammalian expression plasmid, C-Myc tag||RG80148-CM|
|Rat TNFSF8 ORF mammalian expression plasmid, C-HA tag||RG80148-CY|
|Rat TNFSF8 Gene cDNA clone plasmid||RG80148-G|
|Rat TNFSF8 ORF mammalian expression plasmid, N-Flag tag||RG80148-NF|
|Rat TNFSF8 ORF mammalian expression plasmid, N-His tag||RG80148-NH|
|Rat TNFSF8 ORF mammalian expression plasmid, N-Myc tag||RG80148-NM|
|Rat TNFSF8 ORF mammalian expression plasmid, N-HA tag||RG80148-NY|
|Rat TNFSF8 natural ORF mammalian expression plasmid||RG80148-UT|
|Learn more about expression Vectors|
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.